176445-80-0

Basic information

• Product Name: 4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine
• Synonyms: 4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine;4-(Aminomethyl)-4-(dimethylamino)tetrahydro-2H-pyran;4-(Aminomethyl)-4-(dimethylamino)tetrahydro-2H-pyran 95%;[4-(aminomethyl)tetrahydro-2H-pyran-4-yl]dimethylamine;4-(aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine(SALTDATA: FREE);2H-Pyran-4-MethanaMine,4-(diMethylaMino)tetrahydro-;4-(Aminomethyl)-4-(dimethylamino)tetrahydro-2H-pyran95%;(4-Aminomethyl-tetrahydro-pyran-4-yl)-dimethyl-amine
• CAS NO: 176445-80-0
• Molecular Formula: C₈H₁₈N₂O
• Molecular Weight: 158.24132
• Mol File: 176445-80-0.mol

Chemical Properties

• Boiling Point: 231.952 °C at 760 mmHg
• Flash Point: 94.082 °C
• Appearance: /
• Density: 0.99 g/cm³
• Vapor Pressure: 0.061mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: 2-8°C
• PKA: 10.01±0.29(Predicted)
• CAS DataBase Reference: 4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine(176445-80-0)
• EPA Substance Registry System: 4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine(176445-80-0)

Safety Data

• Hazard Codes: C
• HazardClass: IRRITANT
• Hazardous Substances Data: 176445-80-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine is used as a protecting group in chemical synthesis for the development of pharmaceutical compounds. Its stability and selective reactivity make it a valuable tool in the synthesis process, allowing for the creation of complex molecules with specific properties.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine is used as a protecting group in the synthesis of agrochemical compounds. Its ability to selectively react with other molecules enables the production of targeted agrochemicals with desired characteristics.
Used in Academic Research:
4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine is utilized in academic research for the synthesis of various compounds. Its unique structure and properties make it an interesting subject for study, and its use as a protecting group allows researchers to explore new synthetic pathways and develop novel compounds.
Used in Drug Delivery Systems:
4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine has potential applications in drug delivery systems due to its biocompatibility and sustained release properties. It can be used to develop formulations that control the release of active pharmaceutical ingredients, improving the efficacy and safety of drug treatments.
Used in Biomaterials:
4-(Aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-amine's biocompatibility makes it a promising candidate for use in biomaterials. It can be incorporated into materials used for medical devices, implants, or tissue engineering applications, providing a stable and biocompatible platform for these technologies.

InChI:InChI=1/C8H18N2O/c1-10(2)8(7-9)3-5-11-6-4-8/h3-7,9H2,1-2H3

Upstream product

• 519031-87-9 tert-butyl (4-cyanotetrahydro-2H-pyran-4-yl)carbamate 
• 848821-06-7 4-cyanotetrahydro-2H-pyran-4-carboxylic acid 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 176445-77-5 4-(dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 

Downstream Products

• 1299487-35-6 1-((4-(dimethylamino)tetrahydro-2H-pyran-4-yl)methyl)-3-(4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)methyl)phenyl)urea 
• 1416336-99-6 (5-bromo-2-nitrophenyl){[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}amine 
• 1416333-54-4 5-(2-amino-1-{[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}-1H-benzimidazol-6-yl)-2-(methyloxy)-N-phenyl-3-pyridinesulfonamide 
• 1416333-56-6 5-(2-amino-1-{[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}-1H-benzimidazol-6-yl)-N-(4-fluorophenyl)-2-(methyloxy)-3-pyridinesulfonamide 
• 1416337-00-2 (2-amino-5-bromophenyl){[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}amine 
• 1416335-15-3 N-[5-(2-amino-1-{[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}-1H-benzimidazol-6-yl)-2-(methyloxy)-3-pyridinyl]-2,4-difluorobenzenesulfonamide 

Relevant articles and documents

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Preparation method of benzamide derivative and application thereof

The invention provides a preparation method of 4-butoxy-N-((4-(dimethylamino)tetrahydro-2H-pyran-4-yl)methyl)-3, 5-dimethoxybenzamide and an application of the 4-butoxy-N-((4-(dimethylamino)tetrahydro-2H-pyran-4-yl)methyl)-3, 5-dimethoxybenzamide. The 4-butoxy-N-((4-(dimethylamino)tetrahydro-2H-pyran-4-yl)methyl)-3, 5-dimethoxybenzamide has a structure as shown in a formula I which is described in the specification. According to the preparation method provided by the invention, the 4-butoxy-N-((4-(dimethylamino)tetrahydro-2H-pyran-4-yl)methyl)-3, 5-dimethoxybenzamide can be obtained through four steps of reactions including Strecker reaction, reduction reaction, condensation reaction and substitution reaction. The preparation method has the advantages of simple production operation, easily available raw materials, low labor protection requirements, high yield and few byproducts, and is more suitable for industrial mass production.

Preparation method of heterocyclic compound and salt thereof

The invention belongs to the field of organic chemistry and specifically relates to a preparation method of a heterocyclic compound as shown in the formula I and salt thereof. In comparison with the prior art, the invention has the following beneficial effects: the use of the extremely toxic substance cyanide is avoided; there is no cyanide ion residue in the reaction product and the reaction waste such that environmental burden is greatly reduced. In addition, the price of the reaction materials is low; the preparation method is simple; the yield is high; and the preparation method is suitable for large-scale industrial production. It is found unexpectedly that by the adoption of the method of the scheme 4, such as use of a reducing agent and under the acidic condition, the compound VIIIcan be obtained by one-step reaction and the off-protecting group, alkylation and cyano group reduction are realized to obtain the target product. The defect that polystep reactions are required in the prior art is greatly improved.

NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF

Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF

Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

Serotoninergic properties of new conformationally restricted benzamides

A new series of benzamides derived from metoclopramide have been synthesized, in which the vicinal carbon of the basic nitrogen atom of the ethyl chain is situated on the C3, C4, C5 and C6 rings. The diamino derivatives were prepared through Strecker's reaction from the corresponding ketones except for the cyclopropyl derivatives where 1-ethoxy-1-trimethylsiloxy cyclopropane was used as the starting material. The benzamides were prepared using the mixed anhydride method. They were tested in binding assays for D2, 5-HT3 and 5-HT4 receptors. The results show a marked increase in the selectivity and potency of these derivatives for 5-HT3 receptors with regard to metoclopramide (compound 1d: 5-HT3 K(i) = 9.03 nM; 5-HT4 K(i) > 5000; D2 K(i) > 5000). The influences of steric hindrance and hydrophobic properties on the affinity of benzamide derivatives for 5-HT3 receptors were also emphasized by these data. The X-ray crystal structure of compound 1d was compared with that of the minimal energy conformer of BRL 24682, a reference 5-HT3 receptor antagonist benzamide, determined using the Random Search program. Superimposition of the two structures showed a suitable fit between the pharmacophore groups previously determined to be important for 5-HT3 receptor antagonists. On the other hand, the hydrophobic parts of the basic moieties had different spatial occupancies.